Novo Raises Forecast as Wegovy Pill Fuels Sales

AI Summary

Novo Nordisk A/S has raised its profit and sales forecast for the year, crediting the successful introduction of the Wegovy pill for this positive adjustment. The company anticipates smaller declines than previously expected.

Novo Nordisk A/S said this year’s declines won’t be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit and sales will be 12%, compared with 13% earlier. Bloomberg’s Sanne Wass reports from Copenhagen.